Huagongshe화공사 화학 정보 인쇄 보고서 · 연구 참고용
HCID 16137828생성일: 2026년 10월 26일
Tesamorelin
Tesamorelin · Adipotide/FTTP · tesamorel · Tesamorelin 5mg/10mg/20mg · TSM2 · D06655 · Tirelin · Timorelin
https://huagongshe.com/ko/chemical/16137828

식별자 및 물리적 특성
| CAS No. | 218949-48-5 |
|---|
| 분자식 | C221H366N72O67S |
|---|
| 평균 분자량 | 5,136 g/mol |
|---|
| 단동위원소 질량 | 5,132.71664025 g/mol |
|---|
| SMILES | CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)O)[C@@H](C)CC |
|---|
| InChIKey | QBEPNUQJQWDYKU-BMGKTWPMSA-N |
|---|
| PubChem CID | 16137828 |
|---|
| ChEMBL | CHEMBL1237026 |
|---|
| DTXSID | DTXSID00583207 |
|---|
화학 및 물리적 성질
| XLogP | -23.3 |
|---|
| 극성 표면적 | 2,360 |
|---|
| 수소 결합 공여자 수 | 83 |
|---|
| 수소 결합 수용자 수 | 76 |
|---|
| 회전 가능 결합 수 | 187 |
|---|
| 무거운 원자 수 | 361 |
|---|
| 형식 전하 | 0 |
|---|
| 복잡도 | 12,800 |
|---|
| Biologics | Biologic product (Egrifta) -> FDA Purple BookBiologic product (Egrifta SV) -> FDA Purple BookBiologic product (Egrifta WR) -> FDA Purple Book |
|---|
| 저장 조건 | 2-8°C Refrigerator |
|---|
안전 및 규제
| Hepatotoxicity | In clinical trials in patients with HIV-associated lipodystrophy, tesamorelin therapy was not associated with de novo elevations in serum enzymes and, in some studies, was associated with decreases in preexisting ALT elevations, possibly mediated by improvements in nonalcoholic fatty liver. Instances of clinically apparent liver injury attributable to tesamorelin use have not been reported. |
|---|